Unknown

Dataset Information

0

Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development.


ABSTRACT: Objective: Hepatocellular carcinoma (HCC) is a severely lethal cancer that usually originates from chronic liver injury and inflammation. Although progress on diagnosis and treatment is obvious, the cause of HCC remains unclear. In this study, we sought to determine key genes in HCC development. Methods: To identify key regulators during HCC progression, we performed transcriptome sequencing to obtain time series gene expression data from a mouse model with diethylnitrosamine-induced liver tumors and further verified gene expression and function in vitro and in vivo. Results: Among the differentially expressed genes, Cyp2c29 was continuously downregulated during HCC progression. Overexpression of Cyp2c29 suppressed NF-?B activation and proinflammatory cytokine production by increasing the production of 14,15-epoxyeicosatrienoic acid in vitro. Furthermore, overexpression of Cyp2c29 in vivo protected against liver inflammation in mouse models of liver injury induced by both acetaminophen and CCl4. Two human homologs of mouse Cyp2c29, CYP2C8 and CYP2C9, were found to be downregulated in human HCC progression, and their expression was positively correlated with overall survival in patients with HCC (significance: P = 0.046 and 0.0097, respectively). Conclusions: Collectively, through systematic analysis and verification, we determined that Cyp2c29 is a novel gene involved in liver injury and inflammation, which may be a potential biomarker for HCC prevention and prognosis determination.

SUBMITTER: Wang Q 

PROVIDER: S-EPMC7309465 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC5983315 | BioStudies
2016-01-01 | S-EPMC5081228 | BioStudies
2020-01-01 | S-EPMC7352283 | BioStudies
2018-01-01 | S-EPMC5790193 | BioStudies
1000-01-01 | S-EPMC5871907 | BioStudies
2020-01-01 | S-EPMC6997423 | BioStudies
2015-01-01 | S-EPMC4310762 | BioStudies
2019-01-01 | S-EPMC6943354 | BioStudies
1000-01-01 | S-EPMC6120871 | BioStudies
2018-01-01 | S-EPMC6388396 | BioStudies